RSK has been reported to activate mTORC1 by phosphorylating TSC2 on S1798 [32,33], which was confirmed in FLT3-ITD-positive AML cells in the present study (Figure 5A,B,D–F). Here, RPS6KA3 is linked to acute myeloid leukemia.